Monitor whether Artelo can raise sufficient capital by March 31, 2026 to meet Nasdaq's $2.5 million stockholders' equity requirement and avoid delisting. The company's survival depends on this offering's success, making it a high-risk investment with binary outcomes based on funding achievement and regulatory compliance.
Executive Summary
Artelo Biosciences is conducting a best-efforts public offering to raise up to $12 million through the sale of common stock and pre-funded warrants, with net proceeds estimated at $10.9 million. The company, which is focused on developing therapeutics targeting lipid-signaling pathways for conditions like cancer anorexia and chemotherapy-induced neuropathy, is using the funds for working capital and general corporate purposes. This offering comes amid Nasdaq listing compliance challenges and recent bridge financing, highlighting its urgent need for capital to advance clinical programs and maintain exchange listing.
Key Financial Metrics
Key Facts
- Company is raising capital through a best-efforts offering of 1,641,587 shares at $7.31 per share, with estimated net proceeds of $10.9 million after fees and expenses
- Recent interim clinical data shows ART27.13 achieved 6.38% mean weight gain in cancer anorexia patients versus 5.42% loss in placebo group
- Company faces Nasdaq delisting risk due to stockholders' equity below $2.5 million requirement, with compliance deadline of March 30, 2026
- Completed a 1-for-3 reverse stock split on March 10, 2026, reducing outstanding shares from 2.1 million to approximately 736,127
- Recently secured $350,300 in bridge financing through two 12% notes with conversion rights upon default
Financial Impact
Approximately $10.9 million in net proceeds if fully subscribed, representing a significant capital infusion for a company with $600,000 cash balance as of December 31, 2025
Risk Factors
- Risk of Nasdaq delisting if stockholders' equity remains below $2.5 million by March 30, 2026
- Best-efforts offering with no minimum funding requirement means company may not raise needed capital
- Significant dilution for new investors with $4.03 per share dilution at assumed offering price
- Company has accumulated deficit of $63 million and has never generated revenue from product sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001640334-26-000540 |
| Document: artl_ex416.htm | 0001640334-26-000540 |
| Document: artl_ex11.htm | 0001640334-26-000540 |
| Document: 0001640334-26-000540-index-headers.html | 0001640334-26-000540 |
| Document: 0001640334-26-000540-index.html | 0001640334-26-000540 |
| Document: 0001640334-26-000540.txt | 0001640334-26-000540 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 8-K | $3.11 | awaiting T+60 | — | $2.27 (+27.01%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.27 (−39.46%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.27 (−66.77%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.27 (+99.13%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.27 (+99.13%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.27 (+116.20%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.27 (−104.51%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.27 (−55.49%) |
May 18, 2026 22w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.27 (+66.92%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.27 (+55.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers